FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesThe Exponential Growth of Decentralized Trials, Direct-to-Patient and the Future of the Clinical Trials Landscape in Europe
Topics: Conference, Regulatory
Executive Summary
Members
Direct-to-Patient Survey Results Summary
Topics: Health Care, Innovation, Supply Chain
Report
Free
Understanding Blockchain and AI in the Clinical Supply Chain
Topics: Conference, Supply Chain
Video
Members
